No I will not change, I tried but can not find one. Flourainne will stay with RPD:
I was thinking Steelco because I pluged in MFI again and decided against it but found some HSP ( Hydrogen Peroxide derrivative ) news as I had an exchange with E Charters about the LOST SUBs show on cable last week and pressure oxixatation so I would like to PICK STE NYSE but it is not Steelco LOL STE T- is steel a steel ..it is not.
Maple Leaf Foods Inc - In the News
Globe says Maple Leaf, others blossom amid despair
Maple Leaf Foods Inc MFI
Shares issued 90,350,996Jul 22 2002 close $ 15.15
Tuesday July 23 2002In the News
Also Air Canada Inc (AC) In the News
Also Canadian Medical Laboratories Ltd (CLC) In the News
Also Cinram International Inc (CRW) In the News
Also Shoppers Drug Mart Corp (SC) In the News
Also Stelco Inc (STE) In the News
The Globe and Mail reports in its Tuesday, July 23, edition that despair ruled the day on the stock market Monday, but if you take time to look there are certain equities that are fairing well. The Globe's Greg Keenan writes that it is misleading to believe the major stock indexes say everything there is to say about the current investing environment. Mr. Keenan identifies six brand-name stocks with solid year-to-date gains. They include Maple Leaf Foods, up 47.3 per cent through the end of last week, Air Canada, up 37.5 per cent, Stelco, up 42.4 per cent and Shoppers Drug Mart, up 22.9 per cent. One of the more remarkable stocks this year, in Mr. Keenan's view, has been Cinram International, a manufacturer of compact disks and a former favourite growth stock. After years of steady erosion in its share price, Cinram has just about doubled this year as the company moves into production of DVDs. Another eye catcher for Mr. Keenan is Canadian Medical Laboratories, up 53.9 per cent. He says Canadian Medical reaffirms the common sense element of stock picking. As a big player in laboratory testing services, Mr. Keenan says it is bound to benefit from the aging population.
(c) Copyright 2002 Canjex Publishing Ltd. stockwatch.com
old url (better for printing)
STERIS to Work with U.S. Army to Evaluate Technology for Addressing Biochemical Contamination
MENTOR, Ohio, July 29 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE:STE) today announced that its subsidiary, Strategic Technology Enterprises, Inc., and the United States Army Edgewood Chemical Biological Center (ECBC) have entered into an agreement to conduct a collaborative research and development project to evaluate, optimize, and modify STERIS's Vaporized Hydrogen Peroxide (VHP(R)) technology, and demonstrate its effectiveness against biological and chemical warfare agents (BWA/CWA).
Strategic Technology Enterprises will provide technical and decontamination expertise in VHP technology and VHP related equipment. ECBC will provide chemical activation technology and BWA/CWA testing facilities for conducting research to determine the ability of STERIS's VHP technology to provide a single technology to neutralize, contain, decontaminate and/or eradicate biological and chemical agents in a broad range of potential defense applications.
Commenting on the agreement, Les C. Vinney, STERIS's President and Chief Executive Officer, said, "STERIS technologies have been used for many years in the healthcare, pharmaceutical, and research industries. We believe that our technologies can be adapted for use against the threat of biochemical contamination, and for use in other industries to help provide a more secure environment in which people can work and live. We are pleased to be working with ECBC on this important project and supporting the government's efforts to respond to the threat of biochemical terrorism."
STERIS's VHP technology is a low-temperature, dry sterilant that has been proven highly effective against a range of pathogenic organisms and bacterial spores. It is currently used in pharmaceutical production and lab research industries worldwide to decontaminate entire rooms and their contents, sensitive electronic equipment, ductwork, and research isolators.
Strategic Technology Enterprises, Inc., was recently formed by STERIS in order to more effectively focus its efforts to adapt its technologies for use by government and business to address the threat of biochemical contamination. STERIS has received Crisis Exemptions from the United States Environmental Protection Agency (EPA) for four of its technologies to address biochemical contamination. With these exemptions now in place, Strategic Technology Enterprises is involved in the initial stages of project work in this area and is pursuing additional cooperative research and development agreements with other government agencies.
STERIS Corporation is a leading provider of infection prevention, contamination prevention, microbial reduction, and surgical support systems, products, services and technologies to healthcare, scientific, research, and industrial customers throughout the world. Additional information about STERIS can be found on the Company's Website at www.steris.com .
This news release contains statements concerning certain trends and other forward-looking information affecting or relating to the Company and its industry that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward- looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts" and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements. Many of these important factors are outside STERIS's control. Changes in market conditions, including competitive factors and changes in government regulations or the interpretation thereof, could cause actual results to differ materially from the Company's expectations. No assurance can be provided as to any future financial results. The Company does not undertake to update or revise any forward looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include without limitation (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products and applications, (c) the possibility that compliance with the regulations and certification requirements of domestic and foreign authorities may delay or prevent new product introductions or affect the production and marketing of existing products, (d) the potential effects of fluctuations in foreign currencies where the Company does a sizable amount of business, (e) the possibility that implementation of the Company's business improvement initiatives will take longer, cost more or produce lower benefits than anticipated, and (f) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services.
MAKE YOUR OPINION COUNT - Click Here
STERIS Renews Grant to University Hospitals of Cleveland for Infection Prevention Research
MENTOR, Ohio, July 31 /PRNewswire-FirstCall/ -- STERIS Corporation (NYSE:STE) today announced it is renewing its grant to University Hospitals of Cleveland's Division of Infectious Diseases to support research in the area of hospital-acquired and emerging infections and the development of innovative strategies and technologies for preventing infection and contamination. The new grant of $300,000 will help sustain research over the next three years and builds upon a relationship that began with initial funding in 1999.
"We are pleased to continue our support of The Research Institute of University Hospitals of Cleveland," said Dr. Peter A. Burke, STERIS's Senior Vice President and Chief Technology Officer. "As recent studies indicate, hospital-acquired and emerging infections are worldwide healthcare concerns that require the use of significant hospital staff and financial resources. We believe this research has the potential to produce new infection prevention techniques and treatments to help ensure better patient outcomes. This research may also lead to the development of new infection prevention technologies that can be used by researchers and scientists in many other key areas of interest to STERIS. We expect this relationship will continue to enhance the overall research programs of both STERIS Corporation and University Hospitals of Cleveland."
"This joint effort between STERIS Corporation and University Hospitals of Cleveland has been an enormous success and serves as a paradigm for relationships between industry and academia," said Robert Salata, M.D., Chief of the Division of Infectious Diseases at University Hospitals of Cleveland. "Hospital-acquired infections are a growing problem around the country and it is important to continue investigating to learn how to better prevent and treat them."
Under the original STERIS grant, 12 research projects were funded for the treatment of emerging infections and improving infection prevention, involving hepatitis C, tuberculosis, sepsis syndrome and various other antibiotic resistant, hospital-acquired bacterial infections. Additionally, researchers assessed the impact of infections in such areas as the intensive care and bone marrow transplant units of numerous hospitals. The research has resulted in National Institutes of Health grants and six publications. The importance of these activities is reinforced by statistics from the Centers for Disease Control and Prevention, which estimate that 90,000 deaths in the year 2000 were linked to hospital infections, making them the fourth leading cause of death in the United States behind heart disease, cancer and strokes.
University Hospitals Health System (UHHS) is the region's premier healthcare delivery system, serving patients at more than 150 locations throughout northern Ohio. Committed to advanced care and advanced caring, University Hospitals Health System offers the region's largest network of primary care physicians, outpatient centers and hospitals. The System also includes a network of specialty care physicians, skilled nursing, elder health, rehabilitation and home care services, managed care and insurance programs, and the most comprehensive behavioral health services in the region.
STERIS Corporation is a leading provider of infection prevention, contamination prevention, microbial reduction, and surgical support systems, products, services, and technologies to healthcare, scientific, research, and industrial customers throughout the world. Additional information about STERIS can be found on the Company's website at www.steris.com .
This news release contains statements concerning certain trends and other forward-looking information affecting or relating to the Company and its industry that are intended to qualify for the protections afforded "forward- looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of forward- looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "targets," "forecasts" and "seeks," or the negative of such terms or other variations on such terms or comparable terminology. Many important factors could cause actual results to differ materially from those in the forward-looking statements. Many of these important factors are outside STERIS's control. Changes in market conditions, including competitive factors and changes in government regulations or the interpretation thereof, could cause actual results to differ materially from the Company's expectations. No assurance can be provided as to any future financial results. The Company does not undertake to update or revise any forward looking statements even if events make clear that any projected results, express or implied, will not be realized. Other potential risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements include without limitation (a) the potential for increased pressure on pricing that leads to erosion of profit margins, (b) the possibility that market demand will not develop for new technologies, products and applications, (c) the possibility that compliance with the regulations and certification requirements of domestic and foreign authorities may delay or prevent new product introductions or affect the production and marketing of existing products, (d) the potential effects of fluctuations in foreign currencies where the Company does a sizable amount of business, (e) the possibility that implementation of the Company's business improvement initiatives will take longer, cost more or produce lower benefits than anticipated, and (f) the possibility of reduced demand, or reductions in the rate of growth in demand, for the Company's products and services. |
